Skip to content
Annika Bansal – Lifestyle
Author:
Astellas Pharma Inc.
Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
August 24, 2026
Astellas to Spotlight New Research for Geographic Atrophy at ASRS 2026 Annual Meeting
July 9, 2026